SG10201503705UA - Structured Peptide Processing - Google Patents

Structured Peptide Processing

Info

Publication number
SG10201503705UA
SG10201503705UA SG10201503705UA SG10201503705UA SG10201503705UA SG 10201503705U A SG10201503705U A SG 10201503705UA SG 10201503705U A SG10201503705U A SG 10201503705UA SG 10201503705U A SG10201503705U A SG 10201503705UA SG 10201503705U A SG10201503705U A SG 10201503705UA
Authority
SG
Singapore
Prior art keywords
peptide processing
structured peptide
structured
processing
peptide
Prior art date
Application number
SG10201503705UA
Inventor
Gregory Winter Paul
Heinis Christian
Bernard Elise
Loakes David
Vaysburd Marina
Original Assignee
Bicycle Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2009/000301 external-priority patent/WO2009098450A2/en
Application filed by Bicycle Therapeutics Ltd filed Critical Bicycle Therapeutics Ltd
Publication of SG10201503705UA publication Critical patent/SG10201503705UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1044—Preparation or screening of libraries displayed on scaffold proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Ecology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
SG10201503705UA 2009-02-04 2010-02-04 Structured Peptide Processing SG10201503705UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/GB2009/000301 WO2009098450A2 (en) 2008-02-05 2009-02-04 Methods and compositions
GBGB0913775.3A GB0913775D0 (en) 2009-08-06 2009-08-06 Multispecific peptides

Publications (1)

Publication Number Publication Date
SG10201503705UA true SG10201503705UA (en) 2015-06-29

Family

ID=41129757

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201503705UA SG10201503705UA (en) 2009-02-04 2010-02-04 Structured Peptide Processing
SG2011054392A SG173169A1 (en) 2009-02-04 2010-02-04 Structured peptide processing
SG2011054400A SG173460A1 (en) 2009-02-04 2010-02-04 Multispecific peptides

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG2011054392A SG173169A1 (en) 2009-02-04 2010-02-04 Structured peptide processing
SG2011054400A SG173460A1 (en) 2009-02-04 2010-02-04 Multispecific peptides

Country Status (11)

Country Link
US (5) US8685890B2 (en)
EP (3) EP2393519B1 (en)
CN (2) CN102405060B (en)
AU (2) AU2010211282B2 (en)
CA (2) CA2751505C (en)
DK (1) DK2393520T3 (en)
ES (2) ES2896398T3 (en)
GB (1) GB0913775D0 (en)
PL (1) PL2393520T3 (en)
SG (3) SG10201503705UA (en)
WO (3) WO2010089117A1 (en)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0914110D0 (en) * 2009-08-12 2009-09-16 Medical Res Council Peptide libraries
SI2726101T1 (en) 2011-06-30 2018-12-31 Genzyme Corporation Inhibitors of t-cell activation
NO2764140T3 (en) 2011-10-07 2018-01-27
GB201117428D0 (en) 2011-10-07 2011-11-23 Bicycle Therapeutics Ltd Structured polypeptides with sarcosine linkers
CA2873511A1 (en) 2012-05-17 2013-11-21 Ra Pharmaceuticals, Inc. Peptide and peptidomimetic inhibitors
US20140274759A1 (en) * 2013-03-15 2014-09-18 Bicycle Therapeutics Limited Modification of polypeptides
GB201306623D0 (en) 2013-04-11 2013-05-29 Bicycle Therapeutics Ltd Modulation of structured polypeptide specificity
US10364451B2 (en) 2013-05-30 2019-07-30 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
US10392611B2 (en) 2013-05-30 2019-08-27 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
MX2016000666A (en) 2013-07-15 2017-02-15 Univ North Carolina State Protease-resistant peptide ligands.
SG11201602889TA (en) * 2013-10-28 2016-05-30 Bicycle Therapeutics Ltd Novel polypeptides
KR20230133938A (en) 2014-10-29 2023-09-19 바이시클러드 리미티드 Bicyclic peptide ligands specific for mt1-mmp
CN105985524A (en) * 2015-02-10 2016-10-05 北京师范大学 Construction method of polypeptide compound molecule aiming at specific target and having fingerprint identification characteristic
US10385115B2 (en) 2015-03-26 2019-08-20 Duke University Fibronectin type III domain-based fusion proteins
AU2016301391B2 (en) 2015-08-04 2022-07-28 Duke University Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same
US9765117B2 (en) 2015-08-24 2017-09-19 Romek Figa Peptides for treating cancer
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
GB201600903D0 (en) * 2016-01-18 2016-03-02 Bicycle Therapeutics Ltd Peptide derivaties
US11740241B2 (en) * 2016-03-30 2023-08-29 Synovo Gmbh Construct including an anchor, an enzyme recognition site and an indicator region for detecting microbial infection in wounds
GB201607827D0 (en) * 2016-05-04 2016-06-15 Bicycle Therapeutics Ltd Bicyclic peptide-toxin conjugates specific for MT1-MMP
WO2017210476A1 (en) 2016-06-01 2017-12-07 Duke University Nonfouling biosensors
DK3467107T3 (en) * 2016-06-07 2022-06-27 Kaneka Corp RIBOSOM DISPLAY COMPLEX AND ITS MANUFACTURING METHOD
CN109890833A (en) 2016-09-14 2019-06-14 杜克大学 The nanoparticle based on three block polypeptide for delivery of hydrophilic drug
CN110023326A (en) 2016-09-23 2019-07-16 杜克大学 It is unstructured without repetition polypeptide with LCST behavior
US10441663B2 (en) 2016-11-27 2019-10-15 Bicyclerd Limited Methods for treating cancer
EP3559018A1 (en) 2016-12-23 2019-10-30 Bicyclerd Limited Peptide derivatives having novel linkage structures
WO2018127699A1 (en) * 2017-01-06 2018-07-12 Bicyclerd Limited Compounds for treating cancer
WO2018132732A1 (en) 2017-01-12 2018-07-19 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
CN116785451A (en) 2017-02-28 2023-09-22 伊缪诺金公司 Maytansinoid derivatives with self-cleaving peptide linker and conjugates thereof
GB201706477D0 (en) 2017-04-24 2017-06-07 Bicycle Therapeutics Ltd Modification of polypeptides
WO2018213320A1 (en) 2017-05-15 2018-11-22 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
CN111032678A (en) 2017-06-26 2020-04-17 拜西克尔德有限公司 Bicyclic peptide ligands with detectable moieties and uses thereof
EP3658168A4 (en) 2017-06-30 2021-07-14 Duke University Order and disorder as a design principle for stimuli-responsive biopolymer networks
EP3661948B1 (en) * 2017-08-04 2022-06-01 BicycleTx Limited Bicyclic peptide ligands specific for cd137
TWI825046B (en) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Bicyclic peptide ligands specific for epha2
GB201721265D0 (en) * 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
EP3774851A1 (en) * 2018-04-04 2021-02-17 BicycleTX Limited Heterotandem bicyclic peptide complexes
GB201808835D0 (en) * 2018-05-30 2018-07-11 Bicyclerd Ltd Ligands and methods of selecting binding targets for such
US20210283139A1 (en) 2018-06-13 2021-09-16 Amphista Therapeutics Ltd Bifunctional molecules for targeting uchl5
JP2021527137A (en) 2018-06-13 2021-10-11 アンフィスタ セラピューティクス リミテッド Bifunctional molecule for targeting Rpn11
WO2019238886A1 (en) 2018-06-13 2019-12-19 University Of Dundee Bifunctional molecules for targeting usp14
US11180531B2 (en) * 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201810325D0 (en) * 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to PSMA
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
GB201810327D0 (en) * 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to IL-17
WO2020028806A1 (en) 2018-08-02 2020-02-06 Duke University Dual agonist fusion proteins
US20220024982A1 (en) * 2018-12-13 2022-01-27 Bicycletx Limited Bicyclic peptide ligands specific for mt1-mmp
US11613560B2 (en) 2019-05-09 2023-03-28 Bicycletx Limited Bicyclic peptide ligands specific for OX40
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
TW202110485A (en) 2019-07-30 2021-03-16 英商拜西可泰克斯有限公司 Heterotandem bicyclic peptide complex
GB201914233D0 (en) 2019-10-02 2019-11-13 Bicyclerd Ltd Phage cyclisation assay
WO2021064428A1 (en) * 2019-10-03 2021-04-08 Bicycletx Limited Heterotandem bicyclic peptide complexes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780279A (en) * 1990-12-03 1998-07-14 Genentech, Inc. Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
US20030166003A1 (en) * 1999-06-14 2003-09-04 Cochran Andrea G. Structured peptide scaffold for displaying turn libraries on phage
EP1452868A2 (en) * 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
GB2428293A (en) * 2005-07-13 2007-01-24 Domantis Ltd Phage display libraries
US8680022B2 (en) * 2008-02-05 2014-03-25 Bicycle Therapeutics Limited Methods and compositions

Also Published As

Publication number Publication date
US8685890B2 (en) 2014-04-01
WO2010089115A1 (en) 2010-08-12
ES2551580T3 (en) 2015-11-20
CN102405060B (en) 2016-04-13
US20140163201A1 (en) 2014-06-12
AU2010211282B2 (en) 2016-02-11
GB0913775D0 (en) 2009-09-16
US9644201B2 (en) 2017-05-09
CA2751505C (en) 2019-08-20
AU2010211283A1 (en) 2011-08-11
EP2393519A1 (en) 2011-12-14
EP2393520A1 (en) 2011-12-14
CN102405060A (en) 2012-04-04
US20120142541A1 (en) 2012-06-07
EP2393520B1 (en) 2015-07-15
US9670482B2 (en) 2017-06-06
EP2393518A1 (en) 2011-12-14
EP2393518B1 (en) 2021-08-04
CN102405059A (en) 2012-04-04
SG173460A1 (en) 2011-09-29
SG173169A1 (en) 2011-09-29
US20120101253A1 (en) 2012-04-26
WO2010089116A1 (en) 2010-08-12
CA2750969C (en) 2019-05-07
US8778844B2 (en) 2014-07-15
ES2896398T3 (en) 2022-02-24
DK2393520T3 (en) 2015-10-26
CA2750969A1 (en) 2010-08-12
WO2010089115A8 (en) 2011-12-22
CA2751505A1 (en) 2010-08-12
AU2010211283B2 (en) 2015-12-10
EP2393519B1 (en) 2018-01-03
AU2010211282A1 (en) 2011-08-18
CN102405059B (en) 2016-10-12
US20120101256A1 (en) 2012-04-26
US20160046928A1 (en) 2016-02-18
PL2393520T3 (en) 2016-01-29
WO2010089117A1 (en) 2010-08-12

Similar Documents

Publication Publication Date Title
SG10201503705UA (en) Structured Peptide Processing
HK1249580A1 (en) Protein detection via nanoreporters
HK1218558A1 (en) Mirac proteins mirac
EP2507756A4 (en) Processing value-ascertainable items
GB0914110D0 (en) Peptide libraries
EP2415015A4 (en) Barcode processing
ZA201105852B (en) Antibiotic peptides
EP2437770A4 (en) Antimicrobial peptides
EP2431464A4 (en) Aptamer that recognizes peptide
GB0921986D0 (en) Video processing
EP2480578A4 (en) Polypeptide modification
HRP20190262T1 (en) Antimicrobial peptides based on cmap27
GB0803238D0 (en) Parallel processing
EP2417629A4 (en) Semiconductor processing
GB2488454B (en) Multi-granular stream processing
GB0921995D0 (en) Antimicrobial peptides
GB0908435D0 (en) Processes
ZA201109283B (en) Protein
EP2435468A4 (en) Fibromodulin peptide
HK1173358A1 (en) Fviii-derived peptides fviii
GB0915710D0 (en) Processing line
GB0812665D0 (en) Interrupt processing
ZA201203722B (en) Peptide
EP2411406A4 (en) Isoform nell-1 peptide
EP2439209A4 (en) Endokinin c/d-origin peptides